Page 41 - NobleCon19revC2_Neat

aTyr Pharma, Inc.

SELECTED FINANCIAL ITEMS LIFE

(in millions of USD)
CQ4 '22 CQ1 '23 CQ2 '23 CQ3 '23 LTM
Income Statement Key Items
Total Revenue 10.39 NA NA 0.35 10.74
Gross Profit (4.52) (9.38) (9.84) (9.97) (33.71)
Gross Margin -44% NM NM -2823% -314%
EBIT (7.95) (12.79) (13.56) (12.62) (46.91)
EBIT Margin -77% NM NM -3574% -437%
Net Income to Common Shareholders (7.52) (11.95) (12.34) (11.34) (43.16)
Net Margin -72% NM NM -3213% -402%

Balance Sheet Key Items
Total Assets 95.79 136.84 132.75 125.07 125.07
Cash & Short Term Investments 9.98 20.69 12.31 9.79 9.79
% of Assets 10% 15% 9% 8% 8%
Current Assets -Total 80.87 119.45 114.43 107.30 107.30
% of Assets 84% 87% 86% 86% 86%
Total Liabilities 24.50 27.14 26.70 26.87 26.87
% of Assets 26% 20% 20% 21% 21%
Current Liabilities - Total 13.86 13.65 12.37 12.88 12.88
% of Assets 14% 10% 9% 10% 10%
Long Term Debt NA NA NA NA NA
% of Assets NM NM NM NM NM
Total Equity 71.28 109.70 106.05 98.20 98.20
% of Assets 74% 80% 80% 79% 79%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (10.37) (0.59) (12.01) (9.56) (32.53)
Net Cash Flow - Investing 2.00 (38.17) (4.16) 4.38 (35.95)
Net Cash Flow - Financing 0.92 49.50 8.02 2.68 61.11

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Nineteenth Annual Small & Microcap Investor Conference